T1	DISO 58 69	hepatitis B
#1	AnnotatorNotes T1	C0019163; Hepatitis B; Disease or Syndrome
T2	DISO 83 89	cáncer
#2	AnnotatorNotes T2	C0006826; Malignant Neoplasms; Neoplastic Process
T3	PROC 1916 1950	medición de títulos de anticuerpos
#3	AnnotatorNotes T3	C0201478; Hepatitis B surface antibody measurement; Laboratory Procedure
T4	CHEM 131 140	antígenos
#4	AnnotatorNotes T4	C0003320; Antigens; Immunologic Factor
T5	DISO 189 195	cáncer
#5	AnnotatorNotes T5	C0006826; Malignant Neoplasms; Neoplastic Process
T6	CHEM 264 306	vacuna ADN recombinante contra hepatitis B
#6	AnnotatorNotes T6	C1445761; Hepatitis B virus recombinant vaccine; Organic Chemical · Immunologic Factor · Pharmacologic Substance
T7	DISO 295 306	hepatitis B
#7	AnnotatorNotes T7	C0019163; Hepatitis B; Disease or Syndrome
T8	PROC 335 348	quimioterapia
#8	AnnotatorNotes T8	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure + C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T9	PROC 2006 2037	reevaluación de inmunogenicidad
T10	DISO 375 381	cáncer
#9	AnnotatorNotes T10	C0006826; Malignant Neoplasms; Neoplastic Process
T11	PROC 404 464	Estudio prospectivo, bicéntrico, controlado, no aleatorizado
T12	PROC 478 489	diagnóstico
#10	AnnotatorNotes T12	C0011900; Diagnosis; Diagnostic Procedure
T13	DISO 502 508	cáncer
#11	AnnotatorNotes T13	C0006826; Malignant Neoplasms; Neoplastic Process
T14	PROC 552 561	vacunados
#12	AnnotatorNotes T14	C0042196; Vaccination; Therapeutic or Preventive Procedure
T15	CHEM 653 695	vacuna ADN recombinante contra hepatitis B
#13	AnnotatorNotes T15	C1445761; Hepatitis B virus recombinant vaccine; Organic Chemical · Immunologic Factor · Pharmacologic Substance
T16	DISO 684 695	hepatitis B
#14	AnnotatorNotes T16	C0019163; Hepatitis B; Disease or Syndrome
T17	PROC 715 726	diagnóstico
#15	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	DISO 745 760	tumores sólidos
#16	AnnotatorNotes T18	C0280100; Solid Neoplasm; Neoplastic Process
T19	DISO 802 823	tumores hematológicos
#17	AnnotatorNotes T19	C0376545; Hematologic Neoplasms; Neoplastic Process
T20	CHEM 921 932	anticuerpos
#18	AnnotatorNotes T20	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T21	ANAT 933 940	séricos
#19	AnnotatorNotes T21	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T22	DISO 1100 1106	cáncer
#20	AnnotatorNotes T22	C0006826; Malignant Neoplasms; Neoplastic Process
T23	DISO 1228 1234	cáncer
#21	AnnotatorNotes T23	C0006826; Malignant Neoplasms; Neoplastic Process
T24	DISO 1279 1284	tumor
#22	AnnotatorNotes T24	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T25	DISO 1399 1405	cáncer
#23	AnnotatorNotes T25	C0006826; Malignant Neoplasms; Neoplastic Process
T26	PROC 1414 1425	seguimiento
#24	AnnotatorNotes T26	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T27	DISO 1472 1478	cáncer
#25	AnnotatorNotes T27	C0006826; Malignant Neoplasms; Neoplastic Process
T28	PROC 1538 1567	vacunación contra hepatitis B
#26	AnnotatorNotes T28	C0474232; Administration of hepatitis B vaccine; Therapeutic or Preventive Procedure
T29	DISO 1556 1567	hepatitis B
#27	AnnotatorNotes T29	C0019163; Hepatitis B; Disease or Syndrome
T30	CHEM 1572 1595	vacuna ADN recombinante
T31	PROC 1662 1675	quimioterapia
#28	AnnotatorNotes T31	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure + C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T32	DISO 1761 1767	cáncer
#29	AnnotatorNotes T32	C0006826; Malignant Neoplasms; Neoplastic Process
T33	CHEM 1841 1851	adyuvantes
#30	AnnotatorNotes T33	C0001551; Immunologic Adjuvants; Immunologic Factor · Pharmacologic Substance
T34	CHEM 1939 1950	anticuerpos
#31	AnnotatorNotes T34	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	PROC 1994 2003	refuerzos
#32	AnnotatorNotes T35	C0020975; Secondary Immunization; Therapeutic or Preventive Procedure
T36	CHEM 148 155	vacunas
#33	AnnotatorNotes T36	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T37	PROC 909 949	Se midieron anticuerpos séricos anti-HBs
#34	AnnotatorNotes T37	C0201478; Hepatitis B surface antibody measurement; Laboratory Procedure
T38	PROC 1018 1034	títulos anti-HBs
#35	AnnotatorNotes T38	C0201478; Hepatitis B surface antibody measurement; Laboratory Procedure
T39	PROC 1143 1159	títulos anti-HBs
#36	AnnotatorNotes T39	C0201478; Hepatitis B surface antibody measurement; Laboratory Procedure
T40	PROC 1490 1506	títulos anti-HBs
#37	AnnotatorNotes T40	C0201478; Hepatitis B surface antibody measurement; Laboratory Procedure
T41	CHEM 1806 1813	vacunas
#38	AnnotatorNotes T41	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T42	PROC 25 69	primovacunación reforzada contra hepatitis B
T43	LIVB 73 78	niños
#39	AnnotatorNotes T43	C0008059; Child; Age Group
T44	LIVB 179 184	niños
#40	AnnotatorNotes T44	C0008059; Child; Age Group
T45	LIVB 365 370	niños
#41	AnnotatorNotes T45	C0008059; Child; Age Group
T46	LIVB 384 393	Pacientes
#42	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T48	LIVB 468 473	niños
#43	AnnotatorNotes T48	C0008059; Child; Age Group
T49	Date 490 498	reciente
T50	LIVB 522 527	niños
#44	AnnotatorNotes T50	C0008059; Child; Age Group
T51	Duration 574 585	1 y 6 meses
T52	Dose 598 608	20 y 40 μg
T54	Age 617 630	< ó > 10 años
T55	LIVB 828 841	grupo control
#45	AnnotatorNotes T55	C0009932; Control Groups; Group
T56	Dose 881 891	10 o 20 μg
T57	Duration 952 971	los 2, 8 y 12 meses
T61	LIVB 1090 1095	niños
#46	AnnotatorNotes T61	C0008059; Child; Age Group
T63	LIVB 1218 1223	niños
#47	AnnotatorNotes T63	C0008059; Child; Age Group
T66	LIVB 1344 1357	grupo control
#48	AnnotatorNotes T66	C0009932; Control Groups; Group
T67	LIVB 1389 1394	niños
#49	AnnotatorNotes T67	C0008059; Child; Age Group
T68	Duration 1428 1440	los 12 meses
T69	LIVB 1462 1467	niños
#50	AnnotatorNotes T69	C0008059; Child; Age Group
T71	Dose 1622 1629	3 dosis
T72	LIVB 1751 1756	niños
#51	AnnotatorNotes T72	C0008059; Child; Age Group
T73	Duration 1893 1914	los 0, 1, 2 y 6 meses
T74	Duration 1954 1976	octavo y duodécimo mes
T75	Spec_cue 1978 1986	eventual
T77	Duration 1050 1060	octavo mes
T78	Duration 1163 1173	octavo mes
T79	LIVB 1777 1786	población
#52	AnnotatorNotes T79	C1257890; Population; Population Group
T76	PHYS 108 124	respuesta inmune
#53	AnnotatorNotes T76	C0020964; Immune response; Organ or Tissue Function
T47	LIVB 1112 1121	controles
#54	AnnotatorNotes T47	C0009932; Control Groups; Group
T58	PHYS 1700 1716	respuesta inmune
#55	AnnotatorNotes T58	C0020964; Immune response; Organ or Tissue Function
T59	Date 972 985	posvacunación
A1	Assertion T35 Speculated
A2	Assertion T9 Speculated
A3	Population_data T43 Age
A4	Population_data T44 Age
A5	Population_data T45 Age
A6	Population_data T48 Age
A7	Population_data T50 Age
A9	Population_data T61 Age
A10	Population_data T63 Age
A11	Population_data T67 Age
A12	Population_data T69 Age
A13	Population_data T72 Age
T53	Neg_cue 1236 1239	sin
T60	CONC 1240 1250	diferencia
A8	Assertion T60 Negated
#56	AnnotatorNotes T60	C1705241; Delta (difference); Quantitative Concept
R1	Negation Arg1:T53 Arg2:T60	
T62	Quantifier_or_Qualifier 452 464	aleatorizado
A14	Assertion T62 Negated
R2	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T62	
T64	Neg_cue 449 451	no
R3	Negation Arg1:T64 Arg2:T62	
R4	Overlap Arg1:T14 Arg2:T51	
T65	CONC 564 572	tiempo 0
R5	Overlap Arg1:T14 Arg2:T65	
T70	Observation 1 15	Seroconversión
#57	AnnotatorNotes T70	C4042908; Seroconversion; Finding
R8	Experiences Arg1:T43 Arg2:T2	
R9	Experiences Arg1:T43 Arg2:T42	
R10	Causes Arg1:T36 Arg2:T76	
R11	Causes Arg1:T4 Arg2:T76	
R12	Experiences Arg1:T44 Arg2:T76	
R13	Experiences Arg1:T44 Arg2:T5	
R14	Overlap Arg1:T76 Arg2:T5	
T80	Observation 240 254	seroconversión
#58	AnnotatorNotes T80	C4042908; Seroconversion; Finding
R15	Before Arg1:T42 Arg2:T70	
R16	Causes Arg1:T6 Arg2:T80	
T81	CONC 322 348	inicio de la quimioterapia
#59	AnnotatorNotes T81	C4522108; Chemotherapy infusion start date; Quantitative Concept (?)
R17	Overlap Arg1:T80 Arg2:T81	
R18	Experiences Arg1:T45 Arg2:T10	
T82	Observation 353 361	remisión
#60	AnnotatorNotes T82	C0544452; Disease remission; Finding
R6	Experiences Arg1:T45 Arg2:T82	
R7	Before Arg1:T10 Arg2:T82	
R19	Experiences Arg1:T45 Arg2:T8	
R20	Experiences Arg1:T45 Arg2:T6	
R21	Experiences Arg1:T45 Arg2:T80	
R22	Experiences Arg1:T48 Arg2:T13	
R23	Overlap Arg1:T12 Arg2:T49	
T83	Quantifier_or_Qualifier 528 533	sanos
#61	AnnotatorNotes T83	C3898900; Healthy; Qualitative Concept
R24	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T83	
R25	Experiences Arg1:T46 Arg2:T13	
R26	Used_for Arg1:T15 Arg2:T14	
R27	Overlap Arg1:T15 Arg2:T65	
R28	Overlap Arg1:T15 Arg2:T51	
R29	Has_Dose_or_Strength Arg1:T15 Arg2:T52	
R30	Overlap Arg1:T15 Arg2:T17	
T84	Observation 775 783	remisión
#62	AnnotatorNotes T84	C0544452; Disease remission; Finding
R31	Before Arg1:T19 Arg2:T84	
R32	After Arg1:T15 Arg2:T84	
T85	LIVB 539 544	casos
#63	AnnotatorNotes T85	C2986530; Intervention Group; Population Group (?) | C5205743; Experimental Group; Population Group (?)
R33	Experiences Arg1:T85 Arg2:T14	
R34	Has_Age Arg1:T85 Arg2:T54	
R35	Experiences Arg1:T85 Arg2:T18	
R36	Experiences Arg1:T85 Arg2:T19	
R37	Experiences Arg1:T85 Arg2:T84	
R38	Location_of Arg1:T21 Arg2:T37	
R39	Overlap Arg1:T37 Arg2:T57	
R40	Overlap Arg1:T37 Arg2:T59	
R41	Overlap Arg1:T38 Arg2:T77	
T86	Observation 987 1001	Seroconversión
#64	AnnotatorNotes T86	C4042908; Seroconversion; Finding
R43	Overlap Arg1:T86 Arg2:T77	
R44	Experiences Arg1:T61 Arg2:T22	
R45	Experiences Arg1:T61 Arg2:T39	
R46	Experiences Arg1:T47 Arg2:T39	
R47	Overlap Arg1:T39 Arg2:T78	
T87	Observation 1186 1200	seroconversión
#65	AnnotatorNotes T87	C4042908; Seroconversion; Finding
R48	Experiences Arg1:T63 Arg2:T23	
R49	Experiences Arg1:T63 Arg2:T87	
R50	Overlap Arg1:T87 Arg2:T23	
R51	Experiences Arg1:T63 Arg2:T24	
R52	Experiences Arg1:T66 Arg2:T87	
R53	Experiences Arg1:T67 Arg2:T25	
R54	Experiences Arg1:T67 Arg2:T87	
R55	Overlap Arg1:T87 Arg2:T25	
R56	Has_Duration_or_Interval Arg1:T26 Arg2:T68	
R57	Experiences Arg1:T69 Arg2:T27	
R60	Experiences Arg1:T69 Arg2:T40	
R61	Used_for Arg1:T30 Arg2:T28	
#66	AnnotatorNotes T30	C1445761; Hepatitis B virus recombinant vaccine; Organic Chemical · Immunologic Factor · Pharmacologic Substance
R62	Has_Dose_or_Strength Arg1:T30 Arg2:T71	
T88	CONC 1649 1675	inicio de la quimioterapia
#67	AnnotatorNotes T88	C4522108; Chemotherapy infusion start date; Quantitative Concept (?)
R63	Overlap Arg1:T28 Arg2:T88	
R64	Causes Arg1:T28 Arg2:T58	
R65	Experiences Arg1:T72 Arg2:T32	
R66	Overlap Arg1:T58 Arg2:T32	
R67	Experiences Arg1:T72 Arg2:T58	
R68	Experiences Arg1:T72 Arg2:T31	
R69	Experiences Arg1:T72 Arg2:T28	
T89	Observation 1680 1688	remisión
#68	AnnotatorNotes T89	C0544452; Disease remission; Finding
R70	Overlap Arg1:T28 Arg2:T89	
R71	Before Arg1:T32 Arg2:T89	
R72	Experiences Arg1:T72 Arg2:T89	
T90	Quantifier_or_Qualifier 1814 1835	de tercera generación
R73	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T90	
R74	Used_for Arg1:T33 Arg2:T41	
R75	Overlap Arg1:T41 Arg2:T73	
R76	Overlap Arg1:T3 Arg2:T74	
R77	Speculation Arg1:T75 Arg2:T35	
R78	Speculation Arg1:T75 Arg2:T9	
R80	Used_for Arg1:T41 Arg2:T35	
R82	Experiences Arg1:T43 Arg2:T70	
T91	Quantifier_or_Qualifier 161 171	disminuida
#69	AnnotatorNotes T91	C0221099; Impaired; Functional Concept
R83	Has_Quantifier_or_Qualifier Arg1:T76 Arg2:T91	
R42	Overlap Arg1:T87 Arg2:T24	
R58	Experiences Arg1:T79 Arg2:T41	
R59	Experiences Arg1:T79 Arg2:T33	
R84	Experiences Arg1:T79 Arg2:T3	
T92	Quantifier_or_Qualifier 1717 1729	insuficiente
#70	AnnotatorNotes T92	C0231180; Insufficient (qualifier); Qualitative Concept
R79	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T92	
#71	AnnotatorNotes T49	C0332185; Recent; Temporal Concept
#72	AnnotatorNotes T9	C4054739; Immunogenicity Study; Research Activity (?)
A15	Experiencer T43 Patient
A16	Experiencer T44 Patient
A17	Experiencer T45 Patient
A18	Experiencer T48 Patient
A19	Experiencer T50 Patient
A20	Experiencer T46 Patient
A21	Experiencer T85 Patient
A22	Experiencer T61 Patient
A23	Experiencer T47 Patient
A24	Experiencer T63 Patient
A25	Experiencer T69 Patient
A26	Experiencer T67 Patient
A27	Experiencer T66 Patient
A28	Experiencer T72 Patient
A29	Experiencer T79 Patient
A30	Experiencer T55 Patient
